|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Flow cytometric intracellular myeloperoxidase (MPO) staining of leukemic blasts is a useful tool in diagnosis of leukemia subtype.
|
29244249 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nonobese diabetic/severe combined immunodeficient human leukemia mouse model also revealed that PTL preferentially targets the MPO-high AML cells.
|
20699435 |
2010 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hematologic transcription regulators such as CEBPA, CEBPD, and ETV6, and the differentiation associated gene MPO appeared strongly down-regulated, in line with the primitive state of this leukemia.
|
19666867 |
2009 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fluorescence in situ hybridization and vectorette polymerase chain reaction were used to precisely map the chromosomal breakpoint located on the derivative chromosome 17 at 352 bp 5' of MPO, encoding myeloperoxidase a highly expressed protein in myeloid cells, and 2,085 bp 5' of ZNF342 on 19q, encoding a transcription factor expressed in human stem cells and previously implicated in mouse models of leukemia.
|
19255975 |
2009 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Myeloperoxidase (MPO) is an important metabolizing enzyme involved in oxidative stress responses to some environmental carcinogens including benzene, a chemical associated with bone marrow toxicity and leukemia.
|
17479404 |
2007 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase (MPO) is an important metabolizing enzyme involved in oxidative stress responses to some environmental carcinogens including benzene, a chemical associated with bone marrow toxicity and leukemia.
|
17479404 |
2007 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It appears, therefore, that the assessment of MPO mRNA expression enables a further dissection of leukaemia heterogeneity in apparently homogeneous genetic/immunophenotypic ALL subsets.
|
11167741 |
2000 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seven cases originally diagnosed in smears as ALL were rediagnosed as AML (n = 5) or biphenotypic leukaemia (n = 2) because of immunohistochemical reactivity for myeloperoxidase or lysozyme.
|
10889907 |
2000 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NALM-29 cells display biphenotypic characteristics: expression of the intracellular enzyme myeloperoxidase at the mRNA and protein level and cell surface positivity for CD19, CD10, CD13, CD33 and HLA-DR. NALM-29 fulfills EGIL criteria as B-cell precursor (BCP) leukemia B-II type.
|
10456671 |
1999 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of these 25 MPO mRNA(+) leukemias, 10 (40%) are Bcr-Abl positive (with P210 fusion transcript in five patients while the five remaining cases carried P190 transcript).
|
10025890 |
1999 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All FAB M6 and M7 and trilineal leukaemias expressed mRNAs for alpha-globin, glycoprotein IIb (GpIIb), erythropoietin receptor (Epo-R) and thrombopoietin receptor (c-mpl), but not for myeloperoxidase (MPO) which in contrast was expressed in the other FAB-subtype leukaemias.
|
9753066 |
1998 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This higher-expressing SpSp genotype is further shown to be overrepresented in acute promyelocytic leukemia-M3 (APL-M3) and AML-M4, suggesting that higher levels of MPO are associated with an increased risk for this subset of leukemias.
|
9326240 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel human leukemia cell line (Kasumi-3) was established from the blast cells of a 57-year-old man suffering from myeloperoxidase-negative acute leukemia.
|
8613429 |
1996 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ultrastructural studies for MPO activity were performed on four AML-M0; one leukemia showed both gene expression and cytochemical activity, whereas two others contained neither MPO transcripts nor enzyme.
|
7493141 |
1995 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The five different techniques were used to determine the status of MPO expression in 20 randomly chosen leukemia cell lines of myelomonocytic origin.
|
8309258 |
1994 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that the heterogeneity of the heavy subunit of MPO observed in leukocytes or leukemia could be in part produced by partial or complete skipping of an exon.
|
8383257 |
1993 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HL60 cells (a human leukemia cell line) contain high levels of myeloperoxidase and were used as an in vitro model system.
|
8439949 |
1993 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA blot analysis of leukemia cells with myeloperoxidase (MPO) showed an absence of appreciable levels of MPO mRNA.
|
1708434 |
1991 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In four cases of acute undifferentiated leukemias cytochemically negative for MPO, significant levels of MPO transcripts were detected, suggesting a myeloid origin for these cases.
|
2553160 |
1989 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biochemical and ultrastructural effects of monensin on the processing, intracellular transport, and packaging of myeloperoxidase into low and high density compartments of human leukemia (HL-60) cells.
|
2821913 |
1987 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of myeloperoxidase gene expression by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate in human leukemia HL-60 cells.
|
3023307 |
1986 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Leukemias showing a conspicuous lymphoid phenotype, ie, those that are HLA-DR positive, common acute lymphoblastic antigen (cALLA) positive, terminal deoxynucleotidyl transferase (TdT) negative, as well as myeloperoxidase positive (MPO), could be considered so-called mixed leukemias.
|
3864499 |
1985 |